دورية أكاديمية
أعرض في EDS

Copper-binding anticancer peptides from the piscidin family: an expanded mechanism that encompasses physical and chemical bilayer disruption.

التفاصيل البيبلوغرافية
العنوان: Copper-binding anticancer peptides from the piscidin family: an expanded mechanism that encompasses physical and chemical bilayer disruption.
المؤلفون: Comert F; Institute for Bioscience and Biotechnology Research, Rockville, MD, 20850, USA., Heinrich F; Department of Physics, Carnegie Mellon University, Pittsburgh, PA, 15213, USA.; Center for Neutron Research, National Institute of Standards and Technology, Gaithersburg, MD, 20899, USA., Chowdhury A; Institute for Bioscience and Biotechnology Research, Rockville, MD, 20850, USA., Schoeneck M; University of Rochester School of Medicine and Dentistry, Rochester, NY, 14620, USA., Darling C; Department of Biological Sciences, Clemson University, Clemson, SC, 29634, USA., Anderson KW; Institute for Bioscience and Biotechnology Research, Rockville, MD, 20850, USA.; Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, 20899, USA., Libardo MDJ; Department of Chemistry and Institute of Materials Science, University of Connecticut, Storrs, CT, 06269, USA., Angeles-Boza AM; Department of Chemistry and Institute of Materials Science, University of Connecticut, Storrs, CT, 06269, USA., Silin V; Institute for Bioscience and Biotechnology Research, Rockville, MD, 20850, USA., Cotten ML; Department of Applied Science, William and Mary, Williamsburg, VA, 23185, USA. mcotten@wm.edu., Mihailescu M; Institute for Bioscience and Biotechnology Research, Rockville, MD, 20850, USA. emihailescu@ibbr.umd.edu.
المصدر: Scientific reports [Sci Rep] 2021 Jun 16; Vol. 11 (1), pp. 12620. Date of Electronic Publication: 2021 Jun 16.
نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Cell-Penetrating Peptides/*pharmacology , Copper/*chemistry , Lipid Bilayers/*chemistry, A549 Cells ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell-Penetrating Peptides/chemistry ; Fish Proteins/chemistry ; Fish Proteins/pharmacology ; HeLa Cells ; Humans ; Lipid Peroxidation ; Models, Molecular
مستخلص: In the search for novel broad-spectrum therapeutics to fight chronic infections, inflammation, and cancer, host defense peptides (HDPs) have garnered increasing interest. Characterizing their biologically-active conformations and minimum motifs for function represents a requisite step to developing them into efficacious and safe therapeutics. Here, we demonstrate that metallating HDPs with Cu 2+ is an effective chemical strategy to improve their cytotoxicity on cancer cells. Mechanistically, we find that prepared as Cu 2+ -complexes, the peptides not only physically but also chemically damage lipid membranes. Our testing ground features piscidins 1 and 3 (P1/3), two amphipathic, histidine-rich, membrane-interacting, and cell-penetrating HDPs that are α-helical bound to membranes. To investigate their membrane location, permeabilization effects, and lipid-oxidation capability, we employ neutron reflectometry, impedance spectroscopy, neutron diffraction, and UV spectroscopy. While P1-apo is more potent than P3-apo, metallation boosts their cytotoxicities by up to two- and seven-fold, respectively. Remarkably, P3-Cu 2+ is particularly effective at inserting in bilayers, causing water crevices in the hydrocarbon region and placing Cu 2+ near the double bonds of the acyl chains, as needed to oxidize them. This study points at a new paradigm where complexing HDPs with Cu 2+ to expand their mechanistic reach could be explored to design more potent peptide-based anticancer therapeutics.
References: Toxicology. 2003 Jul 15;189(1-2):147-63. (PMID: 12821289)
Sci Rep. 2020 Mar 19;10(1):5045. (PMID: 32193508)
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992. (PMID: 27646922)
Ther Deliv. 2012 Aug;3(8):961-79. (PMID: 22946430)
Int J Mol Sci. 2015 Sep 18;16(9):22711-34. (PMID: 26393585)
Biophys J. 1991 Jan;59(1):174-85. (PMID: 2015382)
ACS Chem Biol. 2018 Apr 20;13(4):844-853. (PMID: 29390186)
Biochim Biophys Acta. 2000 Nov 10;1469(3):159-95. (PMID: 11063882)
Biophys J. 1991 Sep;60(3):568-76. (PMID: 1932548)
Int J Mol Sci. 2019 Oct 24;20(21):. (PMID: 31653020)
J Mol Biol. 1999 Jul 2;290(1):99-117. (PMID: 10388560)
Nature. 2001 Nov 15;414(6861):268-9. (PMID: 11713517)
Biointerphases. 2007 Mar;2(1):21-33. (PMID: 20408633)
J Contemp Dent Pract. 2019 Apr 1;20(4):403-404. (PMID: 31308267)
PLoS One. 2013;8(4):e60462. (PMID: 23577112)
Langmuir. 2013 Jul 9;29(27):8645-56. (PMID: 23745652)
Drug News Perspect. 2003 Mar;16(2):87-92. (PMID: 12792669)
J Antimicrob Chemother. 2007 Dec;60(6):1206-15. (PMID: 17878146)
Nat Rev Drug Discov. 2010 Jun;9(6):447-64. (PMID: 20467424)
Dis Aquat Organ. 2006 Oct 27;72(3):241-52. (PMID: 17190202)
Liver Transpl. 2011 Nov;17 Suppl 3:S34-7. (PMID: 21748845)
Drug Discov Today. 2015 Jan;20(1):122-8. (PMID: 25450771)
Faraday Discuss. 2013;161:499-513; discussion 563-89. (PMID: 23805755)
Nat Rev Drug Discov. 2006 Mar;5(3):219-34. (PMID: 16518375)
Annu Rev Pharmacol Toxicol. 2012;52:337-60. (PMID: 22235859)
Nat Rev Mol Cell Biol. 2008 Feb;9(2):112-24. (PMID: 18216768)
Chemphyschem. 2019 Jan 21;20(2):295-301. (PMID: 30471190)
Cell Mol Life Sci. 2005 Apr;62(7-8):784-90. (PMID: 15868403)
J Am Chem Soc. 2014 Mar 5;136(9):3491-504. (PMID: 24410116)
Nat Chem Biol. 2015 Jan;11(1):9-15. (PMID: 25517383)
Dev Comp Immunol. 2008;32(12):1531-8. (PMID: 18582499)
J Mol Biol. 1976 Jan 25;100(3):359-78. (PMID: 943549)
J Am Chem Soc. 2011 Jun 29;133(25):9912-22. (PMID: 21585196)
J Am Chem Soc. 2012 May 9;134(18):7773-9. (PMID: 22548290)
Front Chem. 2018 Jun 25;6:244. (PMID: 29988520)
Pharmaceuticals (Basel). 2013 May 27;6(6):728-58. (PMID: 24276259)
Biochim Biophys Acta. 2008 Oct;1778(10):2041-50. (PMID: 18440299)
Curr Opin Oncol. 2001 Jul;13(4):218-23. (PMID: 11429477)
Crit Care. 2016 Jun 22;20(1):136. (PMID: 27329228)
J Biomed Sci. 2017 Mar 21;24(1):21. (PMID: 28320393)
J Membr Biol. 2015 Jun;248(3):455-67. (PMID: 25292264)
Sci Rep. 2019 Aug 2;9(1):11282. (PMID: 31375699)
Biophys J. 2011 Mar 16;100(6):1455-62. (PMID: 21402027)
J Am Chem Soc. 2016 Feb 10;138(5):1584-90. (PMID: 26820910)
Sci Rep. 2017 Jan 04;7:39925. (PMID: 28051162)
J Am Chem Soc. 2019 Jun 26;141(25):9837-9853. (PMID: 31144503)
World J Gastroenterol. 2014 Oct 14;20(38):13930-5. (PMID: 25320529)
Zoolog Sci. 2012 May;29(5):327-32. (PMID: 22559967)
Biophys J. 2016 Sep 20;111(6):1258-1266. (PMID: 27653484)
J Am Chem Soc. 2007 Jul 4;129(26):8353-61. (PMID: 17552522)
Biochim Biophys Acta. 2006 Sep;1758(9):1359-72. (PMID: 16815244)
Amino Acids. 2013 Feb;44(2):315-20. (PMID: 22914979)
PLoS One. 2012;7(11):e50263. (PMID: 23226256)
Oncol Rep. 2017 Aug;38(2):637-651. (PMID: 28677775)
Technol Cancer Res Treat. 2014 Apr;13(2):177-94. (PMID: 23919392)
Dalton Trans. 2016 Jun 21;45(23):9436-45. (PMID: 27184978)
EXCLI J. 2018 Jul 25;17:734-752. (PMID: 30190664)
Protein Expr Purif. 2014 Oct;102:63-8. (PMID: 25131859)
Proteins. 2005 Jan 1;58(1):211-21. (PMID: 15508143)
Braz J Med Biol Res. 2013 Jun;46(6):465-85. (PMID: 23828584)
Rev Sci Instrum. 2006 Jul;77(7):74301-7430111. (PMID: 21892232)
Mol Cancer Ther. 2005 Apr;4(4):612-24. (PMID: 15827335)
Biochem Biophys Res Commun. 2015 Jan 2;456(1):446-51. (PMID: 25482446)
Biochim Biophys Acta. 2008 Feb;1778(2):357-75. (PMID: 18078805)
Biochemistry. 1989 Apr 18;28(8):3421-37. (PMID: 2742845)
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2757-64. (PMID: 26902758)
Biochimie. 2015 Jun;113:143-55. (PMID: 25891844)
J Amino Acids. 2012;2012:967347. (PMID: 23316341)
J Biol Chem. 2002 Feb 15;277(7):5030-9. (PMID: 11739390)
Breast Cancer Res. 2011 Oct 24;13(5):R102. (PMID: 22023734)
Nucleic Acids Res. 2015 Jan;43(Database issue):D837-43. (PMID: 25270878)
Eur J Pharmacol. 2009 Dec 25;625(1-3):190-4. (PMID: 19835863)
Biochemistry. 2019 Sep 10;58(36):3802-3812. (PMID: 31448597)
Biochem J. 1997 Mar 1;322 ( Pt 2):425-33. (PMID: 9065759)
Eur J Biochem. 2003 Feb;270(4):675-86. (PMID: 12581207)
J Am Chem Soc. 2006 Apr 26;128(16):5308-9. (PMID: 16620079)
J Phys Chem Lett. 2021 May 13;12(18):4392-4399. (PMID: 33939920)
Biochim Biophys Acta. 2014 Sep;1838(9):2341-9. (PMID: 24674984)
Int J Cancer. 2007 Apr 15;120(8):1721-30. (PMID: 17236204)
Antibiotics (Basel). 2020 Jun 18;9(6):. (PMID: 32570779)
J Immunol Res. 2015;2015:761820. (PMID: 26568964)
Science. 2016 Jan 1;351(6268):aad3292. (PMID: 26722002)
Mar Drugs. 2010 Apr 14;8(4):1213-62. (PMID: 20479976)
Cell Mol Life Sci. 2011 Jul;68(13):2161-76. (PMID: 21573784)
J Phys Chem B. 2015 Dec 10;119(49):15235-46. (PMID: 26569483)
Virol J. 2019 Jul 31;16(1):95. (PMID: 31366370)
Front Microbiol. 2013 Oct 01;4:294. (PMID: 24101917)
Oncotarget. 2016 Jun 28;7(26):40329-40347. (PMID: 27248170)
Drug Resist Updat. 2018 Nov;41:1-25. (PMID: 30471641)
Jpn J Cancer Res. 1999 Apr;90(4):419-24. (PMID: 10363580)
Nature. 1978 Jan 12;271(5641):182-4. (PMID: 579650)
Philos Trans R Soc Lond B Biol Sci. 2016 May 26;371(1695):. (PMID: 27160602)
Biochim Biophys Acta Biomembr. 2020 Jul 1;1862(7):183236. (PMID: 32126226)
Ann Clin Lab Sci. 1990 Sep-Oct;20(5):347-52. (PMID: 2256664)
J Hematol Oncol. 2013 Feb 25;6:19. (PMID: 23442817)
Jpn J Cancer Res. 1997 Feb;88(2):184-90. (PMID: 9119747)
Biochemistry. 2007 Mar 27;46(12):3653-63. (PMID: 17328560)
Int J Cancer. 2006 Jun 15;118(12):3030-44. (PMID: 16404738)
Peptides. 2009 Sep;30(9):1636-42. (PMID: 19539000)
Cancer Res. 1983 Feb;43(2):824-8. (PMID: 6293704)
Biophys J. 2011 Sep 7;101(5):1086-94. (PMID: 21889445)
ChemMedChem. 2014 Aug;9(8):1892-901. (PMID: 24803240)
Trends Immunol. 2014 Sep;35(9):443-50. (PMID: 25113635)
J Biol Chem. 1997 May 2;272(18):12008-13. (PMID: 9115266)
Trends Biotechnol. 2003 Aug;21(8):362-9. (PMID: 12902173)
FEBS J. 2017 Nov;284(21):3662-3683. (PMID: 28892294)
Int J Nanomedicine. 2016 Nov 15;11:6047-6064. (PMID: 27895479)
Biomaterials. 2015 Jun;53:1-11. (PMID: 25890701)
Biophys J. 2009 Apr 8;96(7):2734-43. (PMID: 19348756)
Biopolymers. 2013 Nov;100(6):572-83. (PMID: 23553602)
Front Chem. 2017 Feb 21;5:5. (PMID: 28271058)
J Biol Chem. 2019 Dec 6;294(49):18557-18570. (PMID: 31619519)
Langmuir. 2004 Feb 17;20(4):1311-6. (PMID: 15803712)
Front Pharmacol. 2018 Aug 17;9:922. (PMID: 30174604)
Free Radic Res Commun. 1989;6(1):67-75. (PMID: 2722022)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Cell-Penetrating Peptides)
0 (Fish Proteins)
0 (Lipid Bilayers)
789U1901C5 (Copper)
تواريخ الأحداث: Date Created: 20210617 Date Completed: 20211101 Latest Revision: 20240811
رمز التحديث: 20240812
مُعرف محوري في PubMed: PMC8208971
DOI: 10.1038/s41598-021-91670-w
PMID: 34135370
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-021-91670-w